Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

AstraZeneca AZN recently signed a landmark agreement with the Trump administration to lower drug prices in the United States. The announcement comes just days after Pfizer PFE signed a similar deal ...

Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...

This is read by an automated voice. Please report any issues or inconsistencies here. AstraZeneca becomes second major pharmaceutical company to agree to lower Medicaid drug prices under Trump ...

When seven biopharma executives were asked by senators in February whether they had intentionally blocked generic competition, all of them said no. But several of the companies’ products were included ...

Pfizer (NYSE:PFE) reported breakthrough Phase 3 results for its BRAFTOVI combination in first-line metastatic colorectal cancer and TALZENNA combination in metastatic hormone-sensitive prostate cancer ...

Are we still going to use it? Can we just scrap it? Do we have enough Pfizer? With more changing health advice and discussion ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Good news for Pfizer could be good news for AstraZeneca, for two reasons. First, President Trump hinted in the press conference earlier this week that other deals similar to Pfizer's could be on the ...